{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:31Z","timestamp":1793405311767,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jid.2021.07.164","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T02:11:13Z","timestamp":1631671873000},"page":"613-623.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"PA","title":["Combined Cyclin-Dependent Kinase Inhibition\u00a0Overcomes MAPK\/Extracellular Signal\u2013Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6180-2301","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-4003","authenticated-orcid":false,"given":"Xi-Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9321-1768","authenticated-orcid":false,"given":"Yi-Hui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-3986","authenticated-orcid":false,"given":"Cheng-Jiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0227-5310","authenticated-orcid":false,"given":"Yue-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-8518","authenticated-orcid":false,"given":"Jie-Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-3461","authenticated-orcid":false,"given":"Man-Hon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2561-9868","authenticated-orcid":false,"given":"Re-han-gu-li","family":"Aimaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8814-7378","authenticated-orcid":false,"given":"Hai-Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9634-817X","authenticated-orcid":false,"given":"Qing-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-4193","authenticated-orcid":false,"given":"Zhi-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.07.164_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-016-0391-2","article-title":"A\u00a0phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors","volume":"35","author":"Adjei","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jid.2021.07.164_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.stemcr.2020.03.007","article-title":"Human iPSC-derived neurons and cerebral organoids establish differential effects of germline NF1 gene mutations","volume":"14","author":"Anastasaki","year":"2020","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.jid.2021.07.164_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2021.07.164_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.stemcr.2019.01.001","article-title":"Reprogramming captures the genetic and tumorigenic properties of neurofibromatosis type 1 plexiform neurofibromas [published correction appears in Stem Cell Reports 2019;12:639\u201341]","volume":"12","author":"Carri\u00f3","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.jid.2021.07.164_bib5","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.07.164_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2021.07.164_bib7","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jid.2021.07.164_bib8","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas [published correction appears in N Engl J Med 2020;383:1290]","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.07.164_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s42003-018-0163-y","article-title":"Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1","volume":"1","author":"Isakson","year":"2018","journal-title":"Commun Biol"},{"key":"10.1016\/j.jid.2021.07.164_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.07.164_bib11","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jid.2021.07.164_bib12","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-19-2706","article-title":"RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4\/6 inhibitors","volume":"26","author":"Kohlmeyer","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.07.164_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.expneurol.2017.10.012","article-title":"Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening","volume":"299","author":"Kraniak","year":"2018","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jid.2021.07.164_bib14","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1038\/sj.onc.1210261","article-title":"Tumor microenvironment and neurofibromatosis type I: connecting the GAPs","volume":"26","author":"Le","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.07.164_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","article-title":"Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy","volume":"12","author":"Lim","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jid.2021.07.164_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2021.07.164_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jid.2021.07.164_bib18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A\u00a0phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jid.2021.07.164_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jid.2021.07.164_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A\u00a0RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2021.07.164_bib21","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aas9090","article-title":"NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination","volume":"362","author":"Ruscetti","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jid.2021.07.164_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2021.07.164_bib23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature06046","article-title":"Cdk1 is sufficient to drive the mammalian cell cycle","volume":"448","author":"Santamar\u00eda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jid.2021.07.164_bib24","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Melanoma. Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2021.07.164_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41576-019-0150-2","article-title":"RNA sequencing: the teenage years","volume":"20","author":"Stark","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jid.2021.07.164_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/0008-5472.CAN-20-1992","article-title":"Activation of receptor tyrosine kinases mediates acquired resistance to MEK inhibition in malignant peripheral nerve sheath tumors","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2021.07.164_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120402","article-title":"A\u00a0porcine model of neurofibromatosis type 1 that mimics the human disease","volume":"3","author":"White","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2021.07.164_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00401-019-02086-w","article-title":"NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation","volume":"139","author":"Yu","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jid.2021.07.164_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2018.02.007","article-title":"Wnt7a promotes wound healing by regulation of angiogenesis and inflammation: Issues on diabetes and obesity","author":"Wang","year":"2018","journal-title":"J Dermatol Sci"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21016729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21016729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:26:20Z","timestamp":1758302780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21016729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0022202X21016729"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.07.164","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Cyclin-Dependent Kinase Inhibition\u00a0Overcomes MAPK\/Extracellular Signal\u2013Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.07.164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}